The evidence framework for precision cancer medicine.

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Precision cancer medicine (PCM) aims to personalize cancer therapy based on genomic profiling.
• Current oncology practice relies on randomized controlled trials (RCTs) for standard of care changes.
• PCM faces a challenge due to less precise clinical evidence compared to traditional cytotoxic agents.

Purpose of the Study:

• To highlight the discrepancy between the precision of PCM therapies and the imprecision of supporting clinical evidence.
• To advocate for an evidence-based framework for PCM implementation, moving beyond simple off-label drug prescriptions.
• To identify necessary advancements for PCM to become a standard of care.

Main Methods:

• The study critically reviews the current evidence base for precision cancer medicine.
• It contrasts the precision of targeted therapies with the evidence standards required in oncology.
• It discusses the need for clinical validation of diagnostic tests and efficacy evaluation methods.

Main Results:

• PCM therapies are more precise than traditional agents, but clinical evidence supporting them is often less precise.
• Current implementation of PCM may not be sufficiently evidence-based.
• Significant gaps exist in clinical validation and efficacy assessment for PCM.

Conclusions:

• PCM requires a robust, evidence-based development framework to guide clinical decision-making.
• Simple off-label drug prescription post-genomic sequencing is insufficient for PCM implementation.
• Clinical validation of diagnostics, novel efficacy evaluations, and re-assessed evidence standards are crucial for widespread PCM adoption.